
|Videos|February 23, 2022
Dr. Lowentritt discusses findings from phase 3 ARASENS trial in mHSPC
Author(s)Urology Times staff
“I do think that this helps inform how to choose an agent for this specific stage of the disease,” says Benjamin Lowentritt, MD, FACS.
Advertisement
In this video, Benjamin Lowentritt, MD, FACS, shares his thoughts on the pivotal study, “Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Lowentritt is the director of minimally invasive surgery and robotics and the director of the Prostate Cancer Care Program at Chesapeake Urology in Baltimore, Maryland.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
2
Urocross shows sustained benefit through 24 months post-removal
3
Study suggests tamsulosin deprescribing may be appropriate for select men with BPH
4
Amy E. Krambeck, MD, on choosing between CVAC and FANS for suction-based ureteroscopy
5












